Evidence map›Paper›PMID 26656739›Full record

ArticleScientific reports2015

Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome.

Julie Plée, Sébastien Le Jan, Jérôme Giustiniani, Coralie Barbe, Pascal Joly, Christophe Bedane, Pierre Vabres, François Truchetet, François Aubin, Frank Antonicelli and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02883894 (Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02883894 completednot on this map

Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid

TypeobservationalSponsorCHU de ReimsRan2009 to 2014Enrolled120ConditionsBullous PemphigoidArmsBlood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.American journal of clinical dermatology · 2022
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Julie PléeDepartment of Dermatology, Reims University Hospital, University of Champagne-Ardenne, Reims, France.
Sébastien Le JanLaboratory of Dermatology, Faculty of Medicine of Reims, EA 7319, IFR 53, University of Champagne-Ardenne, Reims, France.
Jérôme GiustinianiLaboratory of Dermatology, Faculty of Medicine of Reims, EA 7319, IFR 53, University of Champagne-Ardenne, Reims, France.
Coralie BarbeClinical Research Unit, Reims University Hospital, Reims, France.
Pascal JolyDepartment of Dermatology, Inserm U905, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Normandy, Rouen, France.
Christophe BedaneDepartment of Dermatology, Limoges University Hospital, Limoges, France.
Pierre VabresDepartment of Dermatology, Dijon University Hospital, Dijon, France.
François TruchetetDepartment of Dermatology, Beauregard Hospital, Thionville, France.
François AubinDepartment of Dermatology, Besançon University Hospital, Besançon, France.
Frank AntonicelliLaboratory of Dermatology, Faculty of Medicine of Reims, EA 7319, IFR 53, University of Champagne-Ardenne, Reims, France.
Philippe BernardDepartment of Dermatology, Reims University Hospital, University of Champagne-Ardenne, Reims, France.
Centre Hospitalier Universitaire de Reims · FRImmunité et Cancer · FRBiotherapy of Genetic Diseases, Inflammatory Disorders and Cancers · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Limoges · FRCHU Dijon Bourgogne · FRHôpital Privé Marseille Beauregard · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bullous pemphigoid (BP) is an inflammatory autoimmune bullous disease involving cytokines and proteases in the process of blister formation. Recently, IL-17 and IL-23 were evidenced in lesional skin and serum of BP patients at time of diagnosis, but their involvement in disease outcome has still not been investigated yet. We then analysed IL-17 and IL-23 serum levels during the first months of follow-up upon treatment. Compared with age- and sex- matched controls, high levels of IL-23 were observed at baseline in BP patients serum (P < 0.01), while IL-17 levels was not. However, some BP patients expressed high IL-17 serum level, independently of disease severity. In these patients, those with ongoing remission reduced IL-17 concentration upon treatment (P < 0.001), whereas IL-17 level remained elevated in patients who relapsed. Meanwhile, IL-23 serum levels increased during the first month of treatment in BP patients who later relapsed (P < 0.01) and MMP-9 serum level was not controlled. Accordingly, we found that both IL-17 and IL-23 increased MMP-9 secretion from leukocytes in-vitro. Then, we showed that elevated IL-17/IL-23 serum concentrations helped to discriminate BP patients who later relapsed. Such uncontrolled inflammatory response raises the question whether these molecules could become biological target for BP patients resistant to steroid treatment.

Indexed as

AgedAged, 80 and overAutoantibodiesBiomarkersCytokinesFemaleFollow-Up StudiesHumansInterleukin-17Interleukin-23MaleMatrix Metalloproteinase 9Patient Outcome AssessmentPemphigoid, BullousPrognosisRecurrenceAutoantibodiesBiomarkersCytokinesInterleukin-17Interleukin-23Matrix Metalloproteinase 9

Identifiers

PMID26656739
PMCPMC4677293
OpenAlexW2214067229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.